CN110678202B - 用于体内核酸表达的系统和方法 - Google Patents

用于体内核酸表达的系统和方法 Download PDF

Info

Publication number
CN110678202B
CN110678202B CN201880027828.2A CN201880027828A CN110678202B CN 110678202 B CN110678202 B CN 110678202B CN 201880027828 A CN201880027828 A CN 201880027828A CN 110678202 B CN110678202 B CN 110678202B
Authority
CN
China
Prior art keywords
composition
injection
expression
nucleic acid
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880027828.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110678202A (zh
Inventor
R·J·德布斯
T·D·海斯
C·汉德姆龙古尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DNARx
Original Assignee
DNARx
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DNARx filed Critical DNARx
Priority to CN202310347530.2A priority Critical patent/CN116392609A/zh
Publication of CN110678202A publication Critical patent/CN110678202A/zh
Application granted granted Critical
Publication of CN110678202B publication Critical patent/CN110678202B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880027828.2A 2017-03-23 2018-03-23 用于体内核酸表达的系统和方法 Active CN110678202B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310347530.2A CN116392609A (zh) 2017-03-23 2018-03-23 用于体内核酸表达的系统和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762475477P 2017-03-23 2017-03-23
US62/475,477 2017-03-23
PCT/US2018/024096 WO2018175932A1 (en) 2017-03-23 2018-03-23 Systems and methods for nucleic acid expression in vivo

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310347530.2A Division CN116392609A (zh) 2017-03-23 2018-03-23 用于体内核酸表达的系统和方法

Publications (2)

Publication Number Publication Date
CN110678202A CN110678202A (zh) 2020-01-10
CN110678202B true CN110678202B (zh) 2023-04-14

Family

ID=63585790

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880027828.2A Active CN110678202B (zh) 2017-03-23 2018-03-23 用于体内核酸表达的系统和方法
CN202310347530.2A Pending CN116392609A (zh) 2017-03-23 2018-03-23 用于体内核酸表达的系统和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310347530.2A Pending CN116392609A (zh) 2017-03-23 2018-03-23 用于体内核酸表达的系统和方法

Country Status (6)

Country Link
US (2) US11541130B2 (https=)
EP (1) EP3600428A4 (https=)
JP (2) JP2020511521A (https=)
CN (2) CN110678202B (https=)
CA (1) CA3057320A1 (https=)
WO (1) WO2018175932A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
JP7014721B2 (ja) 2015-09-18 2022-02-01 ディーエヌエーアールエックス インビボでの核酸発現のためのシステム及び方法
EA201891317A3 (ru) 2015-11-30 2019-04-30 Дьюк Юниверсити Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
WO2018017754A1 (en) 2016-07-19 2018-01-25 Duke University Therapeutic applications of cpf1-based genome editing
EP3600428A4 (en) * 2017-03-23 2020-08-26 Dnarx SYSTEMS AND METHODS FOR THE EXPRESSION OF NUCLEIC ACIDS IN VIVO
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
KR102625470B1 (ko) * 2017-05-31 2024-01-16 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 최적화된 인간 응고 인자 ix 유전자 발현 카세트 및 이의 사용
WO2019144061A1 (en) 2018-01-19 2019-07-25 Duke University Genome engineering with crispr-cas systems in eukaryotes
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020206162A1 (en) * 2019-04-03 2020-10-08 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
WO2021253180A1 (en) 2020-06-15 2021-12-23 Novartis Ag Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators
FR3111913A1 (fr) * 2020-06-30 2021-12-31 Eyevensys Construction d’adn pour le traitement de pathologies oculaires
CN111863118B (zh) * 2020-07-20 2023-09-05 湖南莱博赛医用机器人有限公司 基于tct制片进行tct和dna倍体分析的方法
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
CN116615233A (zh) * 2020-09-25 2023-08-18 Dnarx公司 用于使生物分子在受试者中表达的系统和方法
JP2023548746A (ja) * 2020-10-13 2023-11-21 クリヤ セラピューティクス インコーポレイテッド サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
US20230212610A1 (en) * 2021-12-20 2023-07-06 DNARx Nucleic acid expression using subcutaneous administration
CN115992211B (zh) * 2022-08-10 2025-07-29 南京鼓楼医院 一种用于狼疮性肾炎诊断的血清外泌体tsRNA标志物、探针及其应用
WO2024102972A1 (en) * 2022-11-11 2024-05-16 Beam Therapeutics Inc. Base editing of transthyretin gene
CN115851911B (zh) * 2022-11-25 2025-10-24 南京鼓楼医院 一种用于鉴别狼疮性肾炎的尿液外泌体tsRNA标志物和探针及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074667A (en) * 1996-11-20 2000-06-13 Kinnunen; Paavo Liposomal transfection method
WO2001075092A2 (en) * 2000-03-31 2001-10-11 Genzyme Corporation CpG REDUCED PLASMIDS AND VIRAL VECTORS
US6806084B1 (en) * 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
US20060160184A1 (en) * 2003-05-30 2006-07-20 Merus Biopharmaceuticals, B.V. I.O. Fab library for the preparation of anti VEGF and anti rabies virus fabs
US20090252713A1 (en) * 1996-09-13 2009-10-08 Fabienne Soubrier Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
CN101970687A (zh) * 2007-11-09 2011-02-09 东北大学 用于体内基因输送的自组装胶束样纳米颗粒
WO2016028682A1 (en) * 2014-08-17 2016-02-25 The Broad Institute Inc. Genome editing using cas9 nickases
CN108135845A (zh) * 2015-09-18 2018-06-08 Dnarx公司 用于体内核酸表达的系统和方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133026A (en) 1996-05-31 2000-10-17 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
US6413544B1 (en) 1996-08-19 2002-07-02 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US20020065213A1 (en) * 1998-01-16 2002-05-30 Robert J. Debs Methods and compositions for nonviral gene delivery
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
AU5911899A (en) 1998-09-09 2000-03-27 Genzyme Corporation Methylation of plasmid vectors
EP1250156A4 (en) * 2000-01-19 2004-03-31 Genteric Inc METHOD FOR TRANSFECTING NUCLEIC ACID IN CELLS
WO2001085996A1 (en) 2000-05-09 2001-11-15 Isis Pharmaceuticals, Inc. Methods of obtaining active antisense compounds
US7083782B2 (en) 2000-07-19 2006-08-01 Pepgen Corporation Method of treatment using interferon-tau
AU2001290984A1 (en) 2000-09-18 2002-04-02 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
US20020108132A1 (en) 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
FR2821855B1 (fr) 2001-03-09 2004-04-02 Cayla Genes synthetiques et plasmides bacteriens depourvus de cpg
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
EP2397563A3 (en) 2004-09-17 2012-07-18 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
US20070087045A1 (en) * 2005-10-14 2007-04-19 Industrial Technology Research Institute Lipid carrier and method of preparing the same
EP2023940B1 (en) 2006-05-05 2011-06-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of sglt2
EP2061514B1 (en) * 2006-08-29 2014-11-26 Council of Scientific & Industrial Research An aqueous formulation for possible selective targeting and delivering gene to cancer cells
EP2454368A4 (en) 2009-07-17 2013-01-09 Aaron Thomas Tabor COMPOSITIONS AND METHOD FOR THE GENETIC MODIFICATION OF COSMETIC FUNCTION CELLS FOR IMPROVING THE COSMETIC APPEARANCE PICTURE
CN101812177B (zh) * 2010-01-05 2012-01-25 中国药科大学 类固醇激素修饰的阳离子聚合物及其基因复合物的制备
CN102366411B (zh) * 2011-09-14 2012-12-19 海南灵康制药有限公司 一种地塞米松棕榈酸酯脂质体注射液
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
US20140120157A1 (en) 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
US20160194660A1 (en) 2012-12-21 2016-07-07 Merck Sharp & Dohme Corp. Expression vectors for recombinant protein production in mammalian cells
KR20250012194A (ko) * 2013-06-17 2025-01-23 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
WO2016089862A1 (en) * 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
EP3600428A4 (en) 2017-03-23 2020-08-26 Dnarx SYSTEMS AND METHODS FOR THE EXPRESSION OF NUCLEIC ACIDS IN VIVO
CN116615233A (zh) 2020-09-25 2023-08-18 Dnarx公司 用于使生物分子在受试者中表达的系统和方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6806084B1 (en) * 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
US20090252713A1 (en) * 1996-09-13 2009-10-08 Fabienne Soubrier Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy
US6074667A (en) * 1996-11-20 2000-06-13 Kinnunen; Paavo Liposomal transfection method
WO2001075092A2 (en) * 2000-03-31 2001-10-11 Genzyme Corporation CpG REDUCED PLASMIDS AND VIRAL VECTORS
US20060160184A1 (en) * 2003-05-30 2006-07-20 Merus Biopharmaceuticals, B.V. I.O. Fab library for the preparation of anti VEGF and anti rabies virus fabs
CN101970687A (zh) * 2007-11-09 2011-02-09 东北大学 用于体内基因输送的自组装胶束样纳米颗粒
WO2016028682A1 (en) * 2014-08-17 2016-02-25 The Broad Institute Inc. Genome editing using cas9 nickases
CN108135845A (zh) * 2015-09-18 2018-06-08 Dnarx公司 用于体内核酸表达的系统和方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Combined delivery of dexamethasone and plasmid DNA in an animal model of LPS-induced acute lung injury;Hyun Ah Kim et al，;《Journal of Controlled Release》;20110706;第156卷;第60-69页 *
Liposomal Delivery of Dexamethasone Attenuates Prostate Cancer Bone Metastatic Tumor Growth In Vivo;Jan Kroon, et al.,;《Prostate》;20150630;第75卷(第8期);第815-824页 *
The impact of intragenic CpG content on gene expression;Asli Petra Bauer, et al.,;《Nucleic Acids Res》;20100731;第38卷(第12期);第3891-3908页 *

Also Published As

Publication number Publication date
US20180280539A1 (en) 2018-10-04
JP2020511521A (ja) 2020-04-16
US11541130B2 (en) 2023-01-03
EP3600428A1 (en) 2020-02-05
EP3600428A4 (en) 2020-08-26
CN116392609A (zh) 2023-07-07
JP2024116286A (ja) 2024-08-27
CA3057320A1 (en) 2018-09-27
CN110678202A (zh) 2020-01-10
US20240033376A1 (en) 2024-02-01
WO2018175932A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
CN110678202B (zh) 用于体内核酸表达的系统和方法
AU2022203195B2 (en) Mnd promoter chimeric antigen receptors
KR102869944B1 (ko) 조작된 면역자극성 박테리아 균주 및 이의 용도
AU2019377141B2 (en) Enhanced systems for cell-mediated oncolytic viral therapy
KR102787119B1 (ko) 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
AU2022200903C1 (en) Engineered Cascade components and Cascade complexes
TW202237826A (zh) 基因編輯的自然殺手細胞
RU2761631C2 (ru) Белки rsv в предшествующей слиянию конформации и их применение
KR20230019843A (ko) 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물
KR20210143230A (ko) 뉴클레오티드 서열을 편집하기 위한 방법 및 조성물
KR102652494B1 (ko) 전장 t-세포 수용체 오픈 리딩 프레임의 신속한 조립 및 다양화를 위한 2-성분 벡터 라이브러리 시스템
KR20240037185A (ko) 키메라 공동자극 수용체, 케모카인 수용체, 및 세포 면역치료에서의 이의 용도
KR20230086663A (ko) 대상체에서 생체분자를 발현하기 위한 시스템 및 방법
KR20220078607A (ko) 융합 단백질들을 이용한 tcr 재프로그래밍을 위한 조성물 및 방법들
CN110225765B (zh) 减毒猪流感疫苗以及其制备和使用方法
US20260021181A1 (en) Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
KR102727950B1 (ko) 헬퍼 플라스미드 기반 가틀리스 아데노바이러스 생산 시스템
RU2774631C1 (ru) Сконструированные компоненты cascade и комплексы cascade
RU2852571C2 (ru) Белки rsv f в предшествующей слиянию конформации и их применение
RU2799573C2 (ru) Химерные антигенные рецепторы с mnd-промотором

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant